Business
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society ...
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2022 \n \n\nData from Ongoing Phase 1/2 Study of INT230-6 Alone or in Combination with Ipilimumab (INTENSITY# IT-01; BMS# CA184-592) Selected for Oral Podium Presentation \nExploratory Kaplan Meier Analysis of the refractory Sarcoma Population Shows that dosing INT230-6 Equivalent to 40% or More of the Patient's Tumor Burden During the Course of Therapy Results in a Median Overall Survival of 715 Days Compared to a mOS of 205 days or a Historical Refractory Sarcoma Control\nWESTPORT, Conn., Nov. 18, 2022 /PRNewswire/ -- Intensity Therapeutics, Inc. (\"Intensity\"), a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its open-label phase 1/2 study of novel lead asset, INT230-6, as a monotherapy or in combination with ipilimumab in adult subjects with metastatic sarcomas, will be presented today in an oral podium presentation, at the Connective Tissue Oncology Society Annual Meeting (CTOS) being held at the Vancouver Convention Center in Vancouver, BC, Canada from November 16 -19, 2022.\n\"Preliminary data suggests that INT230-6, as a monotherapy or in combination with the immune checkpoint blocker ipilimumab, demonstrates direct tumor killing in soft tissue sarcoma (STS) and elicits an anti-cancer immune response within the injected tumor,\" stated Matthew Ingham, M.D., assistant professor of medicine in the Division of Hematology and Oncology, Columbia University Vagelos College of Physicians and Surgeons, and a principal investigator for the trial. \"To date, INT230-6 treatment related adverse events are mostly low grade and the drug is well-tolerated either as a monotherapy or in combination with ipilimumab. Additionally, in patients who had 40% or more of their tumor burden treated with INT230-6, an exploratory analysis showed that overall survival was improved when compared to historical benchmarks for this patient population.\"\nLewis H. Bender, President and Chief Executive Officer...